RxDoctor Payments Data

Chool Liyanapatabendi, MD

Internal Medicine · Park Ridge, ILNPI 1689976649

Payments from drug & device makers

$1,520in general payments, 2019–2025

Across 42 payments — averaging $36.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$360
  • Angiodynamics, Inc.$318
  • Cardiovascular Systems Inc.$304
  • Novartis$139
  • Sunovion Pharmaceuticals Inc.$139
  • Teva Pharmaceuticals USA, Inc.$62
  • plus $197 from 6 others

What the payments were for

  • Food & beverage$1,520100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,520 in reported general payments places this provider in the 80th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$78,424
Medicare patients
141
Services billed
738

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,018$305,051
Tetrabenazine14$109,862
IngrezzaValbenazine Tosylate41$102,888
XareltoRivaroxaban338$94,754
EnbrelEtanercept20$63,180
AvycazCeftazidime/Avibactam20$57,366
OtezlaApremilast19$45,355
TivicayDolutegravir Sodium29$38,160
JardianceEmpagliflozin85$37,851
Invega SustennaPaliperidone Palmitate12$29,955
JanuviaSitagliptin Phosphate64$26,536
Enoxaparin Sodium319$26,318
TradjentaLinagliptin44$26,306
Atorvastatin Calcium1,342$25,564
Risperidone ErRisperidone Microspheres26$20,662

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto, Invega Sustenna$360$124,709350 claims
Astellas Pharma US IncMyrbetriq$16$15,70056 claims
NovartisEntresto$139$12,11945 claims
Sumitomo Pharma America, Inc.Gemtesa$18$10,20041 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Park Ridge

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →